DrugDashboards

Desipramine Hydrochloride

desipramine hydrochloride · DESIPRAMINE HYDROCHLORIDE 50 mg/1 · Tablet · Oral · Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

NDC 23155-0580-01 · 100 TABLET in 1 BOTTLE · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 36% in a year, to $0.2046 per unit — and generics that get this cheap tend to get abandoned rather than defended. 6 Class II recalls hit this product in the past year (Heritage Pharmaceuticals Inc). One of its named manufacturing plants, USV Private Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Put together: worth watching — several of the pressures that precede supply trouble are present at once. Historically, drugs in this position went on to a new shortage within 90 days about 0.3% of the time — roughly 2× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.2046per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicaid generic ceiling (FUL)$0.2046per TABweighted avg manufacturer price $0.1077 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 50742-0114-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.6264per unit
middle half $0.4692$1.09 · 5,496 plans · Apr 1, 2026
Est. net of rebates
≈ $0.6264
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 4 · prior auth 47% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$1.00$2.00$3.00Aug 2017Sep 2026$0.2046
73 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$6.14
#90 count
$18.41

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$588
27 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

38Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 4 active manufacturers+5
  • Class I/II recall in past 12 months+15
  • price down 34% year over year+8
  • manufacturer plans to discontinue+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.3%chance of a new FDA shortage posting for desipramine hydrochloride (oral solid) in the next 90 days

6 Class I/II recall(s) in 12 months · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 2× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA207433
TE code
Approval date
May 5, 2016
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation Desipramine Hydrochloride, Tablet, 10 mg (NDC 23155-578-01)Aug 12, 2025
  • Planned discontinuation Desipramine Hydrochloride, Tablet, 100 mg (NDC 23155-582-01)Aug 12, 2025
  • Planned discontinuation Desipramine Hydrochloride, Tablet, 25 mg (NDC 23155-579-01)Aug 12, 2025
  • Planned discontinuation Desipramine Hydrochloride, Tablet, 50 mg (NDC 23155-580-01)Aug 12, 2025
  • Planned discontinuation Desipramine Hydrochloride, Tablet, 75 mg (NDC 23155-581-01)Aug 12, 2025

Recalls (this NDC)

  • Class II · OngoingOct 6, 2025
    Heritage Pharmaceuticals IncCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
  • Class II · OngoingOct 6, 2025
    Heritage Pharmaceuticals IncCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
  • Class II · OngoingOct 6, 2025
    Heritage Pharmaceuticals IncCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
  • Class II · OngoingOct 6, 2025
    Heritage Pharmaceuticals IncCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
  • Class II · OngoingOct 6, 2025
    Heritage Pharmaceuticals IncCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
  • Class II · OngoingOct 6, 2025
    Heritage Pharmaceuticals IncCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Manufacturers of desipramine hydrochloride (Tablet)

LabelerStrengthFirst seenLast seen
Chartwell RX, LLCDESIPRAMINE HYDROCHLORIDE 10 mg/1Jul 15, 2026Sep 2, 2026
Chartwell RX, LLCDESIPRAMINE HYDROCHLORIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Chartwell RX, LLCDESIPRAMINE HYDROCHLORIDE 150 mg/1Jul 15, 2026Sep 2, 2026
Chartwell RX, LLCDESIPRAMINE HYDROCHLORIDE 25 mg/1Jul 15, 2026Sep 2, 2026
Chartwell RX, LLCDESIPRAMINE HYDROCHLORIDE 50 mg/1Jul 15, 2026Sep 2, 2026
Chartwell RX, LLCDESIPRAMINE HYDROCHLORIDE 75 mg/1Jul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.DESIPRAMINE HYDROCHLORIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.DESIPRAMINE HYDROCHLORIDE 25 mg/1Jul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.DESIPRAMINE HYDROCHLORIDE 75 mg/1Jul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.DESIPRAMINE HYDROCHLORIDE 10 mg/1Jul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.DESIPRAMINE HYDROCHLORIDE 50 mg/1Jul 15, 2026Sep 2, 2026
Ingenus Pharmaceuticals, LLCDESIPRAMINE HYDROCHLORIDE 50 mg/1Jul 15, 2026Sep 2, 2026
Ingenus Pharmaceuticals, LLCDESIPRAMINE HYDROCHLORIDE 10 mg/1Jul 15, 2026Sep 2, 2026
Ingenus Pharmaceuticals, LLCDESIPRAMINE HYDROCHLORIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Ingenus Pharmaceuticals, LLCDESIPRAMINE HYDROCHLORIDE 25 mg/1Jul 15, 2026Sep 2, 2026
Ingenus Pharmaceuticals, LLCDESIPRAMINE HYDROCHLORIDE 150 mg/1Jul 15, 2026Sep 2, 2026
Ingenus Pharmaceuticals, LLCDESIPRAMINE HYDROCHLORIDE 75 mg/1Jul 15, 2026Sep 2, 2026
Remedyrepack Inc.DESIPRAMINE HYDROCHLORIDE 10 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Desipramine Hydrochloride — NDC 23155-0580-01," retrieved September 3, 2026, https://drugdashboards.com/drug/23155058001.

Free to cite with attribution — see how the data is put together.